{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,2,5]],"date-time":"2026-02-05T09:44:34Z","timestamp":1770284674028,"version":"3.49.0"},"reference-count":106,"publisher":"Elsevier BV","issue":"5","license":[{"start":{"date-parts":[[2022,9,1]],"date-time":"2022-09-01T00:00:00Z","timestamp":1661990400000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2022,9,1]],"date-time":"2022-09-01T00:00:00Z","timestamp":1661990400000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2022,9,1]],"date-time":"2022-09-01T00:00:00Z","timestamp":1661990400000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-017"},{"start":{"date-parts":[[2022,9,1]],"date-time":"2022-09-01T00:00:00Z","timestamp":1661990400000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-037"},{"start":{"date-parts":[[2022,9,1]],"date-time":"2022-09-01T00:00:00Z","timestamp":1661990400000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-012"},{"start":{"date-parts":[[2022,9,1]],"date-time":"2022-09-01T00:00:00Z","timestamp":1661990400000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-029"},{"start":{"date-parts":[[2022,9,1]],"date-time":"2022-09-01T00:00:00Z","timestamp":1661990400000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-004"}],"content-domain":{"domain":["clinicalkey.com","clinicalkey.com.au","clinicalkey.es","clinicalkey.fr","clinicalkey.jp","surveyophthalmol.com","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Survey of Ophthalmology"],"published-print":{"date-parts":[[2022,9]]},"DOI":"10.1016\/j.survophthal.2022.03.003","type":"journal-article","created":{"date-parts":[[2022,3,9]],"date-time":"2022-03-09T11:02:36Z","timestamp":1646823756000},"page":"1391-1404","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":8,"title":["Use of interferon alpha 2b to manage conjunctival primary acquired melanosis and conjunctival melanoma"],"prefix":"10.1016","volume":"67","author":[{"ORCID":"https:\/\/orcid.org\/0000-0002-6258-0333","authenticated-orcid":false,"given":"Pau","family":"Cid-Bertomeu","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-3832-6981","authenticated-orcid":false,"given":"Valent\u00edn","family":"Huerva","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"78","reference":[{"issue":"1","key":"10.1016\/j.survophthal.2022.03.003_bib0001","doi-asserted-by":"crossref","first-page":"3","DOI":"10.1016\/j.survophthal.2003.10.008","article-title":"Tumors of the conjunctiva and cornea","volume":"49","author":"Shields","year":"2004","journal-title":"Surv Ophthalmol"},{"issue":"1","key":"10.1016\/j.survophthal.2022.03.003_bib0002","doi-asserted-by":"crossref","first-page":"26","DOI":"10.1016\/j.survophthal.2016.06.001","article-title":"Advances in the management of conjunctival melanoma","volume":"62","author":"Vora","year":"2017","journal-title":"Surv Ophthalmol"},{"issue":"5","key":"10.1016\/j.survophthal.2022.03.003_bib0003","doi-asserted-by":"crossref","first-page":"476","DOI":"10.1136\/bjo.82.5.476","article-title":"Liarikos S. Topical mitomycin C chemotherapy for conjunctival melanoma and PAM with atypia","volume":"82","author":"Finger","year":"1998","journal-title":"Br J Ophthalmol"},{"issue":"1","key":"10.1016\/j.survophthal.2022.03.003_bib0004","first-page":"51","volume":"110","author":"Fujioka","year":"2006","journal-title":"Nippon Ganka Gakkai Zasshi"},{"issue":"1","key":"10.1016\/j.survophthal.2022.03.003_bib0005","doi-asserted-by":"crossref","first-page":"124","DOI":"10.1016\/j.ajo.2007.08.027","article-title":"Topical interferon alfa in the treatment of conjunctival melanoma and primary acquired melanosis complex","volume":"145","author":"Finger","year":"2008","journal-title":"Am J Ophthalmol"},{"key":"10.1016\/j.survophthal.2022.03.003_bib0006","article-title":"Evaluation of interferon alpha 2b as adjunctive therapy for conjunctival melanoma","volume":"15","author":"Benage","year":"2019","journal-title":"Am J Ophthalmol Case Rep"},{"issue":"1","key":"10.1016\/j.survophthal.2022.03.003_bib0007","doi-asserted-by":"crossref","first-page":"29","DOI":"10.3109\/01676830.2015.1093509","article-title":"Evaluation of a short-term topical interferon \u03b1-2b treatment for histologically proven melanoma and primary acquired melanosis with atypia","volume":"35","author":"Garip","year":"2016","journal-title":"Orbit"},{"issue":"11","key":"10.1016\/j.survophthal.2022.03.003_bib0008","doi-asserted-by":"crossref","first-page":"2271","DOI":"10.1007\/s00417-017-3754-2","article-title":"Long-term follow-up of conjunctival melanoma treated with topical interferon alpha-2b eye drops as adjunctive therapy following surgical resection","volume":"255","author":"Kikuchi","year":"2017","journal-title":"Graefes Arch Clin Exp Ophthalmol"},{"issue":"6","key":"10.1016\/j.survophthal.2022.03.003_bib0009","doi-asserted-by":"crossref","first-page":"673","DOI":"10.1016\/S0161-6420(84)34245-2","article-title":"Conjunctival melanosis and melanoma","volume":"91","author":"Folberg","year":"1984","journal-title":"Ophthalmology"},{"issue":"2","key":"10.1016\/j.survophthal.2022.03.003_bib0010","doi-asserted-by":"crossref","first-page":"147","DOI":"10.1016\/S0161-6420(89)32920-4","article-title":"Clinicopathologic characteristics of premalignant and malignant melanocytic lesions of the conjunctiva","volume":"96","author":"Jakobiec","year":"1989","journal-title":"Ophthalmology"},{"key":"10.1016\/j.survophthal.2022.03.003_bib0011","doi-asserted-by":"crossref","first-page":"521","DOI":"10.2147\/OPTH.S38415","article-title":"Conjunctival melanoma: a review of conceptual and treatment advances","volume":"6","author":"Lim","year":"2013","journal-title":"Clin Ophthalmol"},{"issue":"8","key":"10.1016\/j.survophthal.2022.03.003_bib0012","doi-asserted-by":"crossref","first-page":"786","DOI":"10.1111\/j.1442-9071.2008.01888.x","article-title":"Conjunctival melanoma and melanosis: a reappraisal of terminology, classification and staging","volume":"36","author":"Damato","year":"2008","journal-title":"Clin Exp Ophthalmol"},{"issue":"2","key":"10.1016\/j.survophthal.2022.03.003_bib0013","doi-asserted-by":"crossref","first-page":"117","DOI":"10.1177\/107327481602300205","article-title":"Management of primary acquired melanosis, nevus, and conjunctival melanoma","volume":"23","author":"Kao","year":"2016","journal-title":"Cancer Control"},{"issue":"2","key":"10.1016\/j.survophthal.2022.03.003_bib0014","doi-asserted-by":"crossref","first-page":"142","DOI":"10.1038\/eye.2012.254","article-title":"Conjunctival melanoma and melanocytic intra-epithelial neoplasia","volume":"27","author":"Kenawy","year":"2013","journal-title":"Eye (Lond)"},{"issue":"3","key":"10.1016\/j.survophthal.2022.03.003_bib0015","doi-asserted-by":"crossref","first-page":"371","DOI":"10.1007\/s40257-019-00500-3","article-title":"Conjunctival melanoma: current treatments and future options","volume":"21","author":"Grimes","year":"2020","journal-title":"Am J Clin Dermatol"},{"key":"10.1016\/j.survophthal.2022.03.003_bib0016","doi-asserted-by":"crossref","first-page":"678","DOI":"10.1093\/oxfordjournals.bmb.a072986","article-title":"Pathology of ocular melanomas","volume":"51","author":"McCartney","year":"1995","journal-title":"Br Med Bull"},{"issue":"9","key":"10.1016\/j.survophthal.2022.03.003_bib0017","doi-asserted-by":"crossref","first-page":"569","DOI":"10.1007\/BF00448801","article-title":"Malignant melanoma of the conjunctiva: occurrence and survival following surgery and radiotherapy in a Danish population","volume":"234","author":"Norregaard","year":"1996","journal-title":"Graefes Arch Clin Exp Ophthalmol"},{"issue":"5","key":"10.1016\/j.survophthal.2022.03.003_bib0018","doi-asserted-by":"crossref","first-page":"218","DOI":"10.1016\/j.oftal.2019.01.008","article-title":"A retrospective review of conjunctival melanoma: presentation, treatment and evolution","volume":"94","author":"Pacheco","year":"2019","journal-title":"Arch Soc Esp Oftalmol"},{"issue":"3","key":"10.1016\/j.survophthal.2022.03.003_bib0019","doi-asserted-by":"crossref","first-page":"289","DOI":"10.1111\/j.1755-3768.1992.tb08566.x","article-title":"Conjunctival malignant melanoma in Sweden 1969-91","volume":"70","author":"Seregard","year":"1992","journal-title":"Acta Ophthalmol (Copenh)"},{"issue":"2","key":"10.1016\/j.survophthal.2022.03.003_bib0020","doi-asserted-by":"crossref","first-page":"389","DOI":"10.1016\/j.ophtha.2010.06.021","article-title":"Conjunctival melanoma: outcomes based on tumor origin in 382 consecutive cases","volume":"118","author":"Shields","year":"2011","journal-title":"Ophthalmology"},{"key":"10.1016\/j.survophthal.2022.03.003_bib0021","doi-asserted-by":"crossref","first-page":"122","DOI":"10.1016\/j.clindermatol.2008.09.010","article-title":"Ocular melanoma: relatively rare but requiring respect","volume":"27","author":"Shields","year":"2009","journal-title":"Clin Dermatol"},{"key":"10.1016\/j.survophthal.2022.03.003_bib0022","doi-asserted-by":"crossref","first-page":"106","DOI":"10.1016\/j.ajo.2016.09.034","article-title":"Conjunctival Tumors in 5002 Cases. Comparative analysis of benign versus malignant counterparts. The 2016 James D. Allen Lecture","volume":"173","author":"Shields","year":"2017","journal-title":"Am J Ophthalmol"},{"issue":"4","key":"10.1016\/j.survophthal.2022.03.003_bib0023","doi-asserted-by":"crossref","first-page":"501","DOI":"10.1007\/s40123-019-00219-8","article-title":"Management issues in conjunctival tumours: conjunctival melanoma and primary acquired melanosis","volume":"8","author":"Cohen","year":"2019","journal-title":"Ophthalmol Ther."},{"key":"10.1016\/j.survophthal.2022.03.003_bib0024","first-page":"61","article-title":"Primary acquired melanosis of the conjunctiva: experience with 311 eyes","volume":"105","author":"Shields","year":"2007","journal-title":"Trans Am Ophthalmol Soc"},{"issue":"2","key":"10.1016\/j.survophthal.2022.03.003_bib0025","doi-asserted-by":"crossref","first-page":"129","DOI":"10.1016\/S0046-8177(85)80061-7","article-title":"Primary acquired melanosis of the conjunctiva","volume":"16","author":"Folberg","year":"1985","journal-title":"Hum Pathol"},{"key":"10.1016\/j.survophthal.2022.03.003_bib0026","doi-asserted-by":"crossref","first-page":"3137","DOI":"10.2147\/OPTH.S271569","article-title":"Update on Genetics, Epigenetics and Targeted Molecular and Immune-Based Therapies","volume":"14","author":"Gkiala","year":"2020","journal-title":"Clin Ophthalmol"},{"issue":"4","key":"10.1016\/j.survophthal.2022.03.003_bib0027","doi-asserted-by":"crossref","first-page":"787","DOI":"10.1007\/s12253-018-0419-3","article-title":"Conjunctival melanoma - epidemiological trends and features","volume":"24","author":"Ka\u0161telan","year":"2018","journal-title":"Pathol Oncol Res"},{"issue":"3","key":"10.1016\/j.survophthal.2022.03.003_bib0028","doi-asserted-by":"crossref","first-page":"418","DOI":"10.1016\/j.ajo.2007.10.022","article-title":"Population-based incidence of conjunctival melanoma in various races and ethnic groups and comparison with other melanomas","volume":"145","author":"Hu","year":"2008","journal-title":"Am J Ophthalmol"},{"issue":"6","key":"10.1016\/j.survophthal.2022.03.003_bib0029","doi-asserted-by":"crossref","first-page":"601","DOI":"10.1001\/jamaophthalmol.2020.0531","article-title":"Incidence and Survival of Patients With Conjunctival Melanoma in Europe","volume":"138","author":"Virgili","year":"2020","journal-title":"JAMA Ophthalmol"},{"issue":"4","key":"10.1016\/j.survophthal.2022.03.003_bib0030","doi-asserted-by":"crossref","first-page":"577","DOI":"10.1016\/j.amjoto.2019.05.013","article-title":"Prognostic factors and survival for malignant conjunctival melanoma and squamous cell carcinoma over four decades","volume":"40","author":"Abt","year":"2019","journal-title":"Am J Otolaryngol"},{"issue":"11","key":"10.1016\/j.survophthal.2022.03.003_bib0031","doi-asserted-by":"crossref","first-page":"1524","DOI":"10.1136\/bjo.2009.157933","article-title":"Time trends in the incidence of conjunctival melanoma in Sweden","volume":"93","author":"Triay","year":"2009","journal-title":"Br J Ophthalmol"},{"issue":"11","key":"10.1016\/j.survophthal.2022.03.003_bib0032","doi-asserted-by":"crossref","first-page":"1497","DOI":"10.1001\/archopht.118.11.1497","article-title":"Conjunctival melanoma: risk factors for recurrence, exenteration, metastasis, and death in 150 consecutive patients","volume":"118","author":"Shields","year":"2000","journal-title":"Arch Ophthalmol"},{"issue":"3","key":"10.1016\/j.survophthal.2022.03.003_bib0033","doi-asserted-by":"crossref","first-page":"248","DOI":"10.1097\/00000421-200206000-00009","article-title":"Long-term follow-up of patients with conjunctival melanoma","volume":"25","author":"Werschnik","year":"2002","journal-title":"Am J Clin Oncol"},{"issue":"10","key":"10.1016\/j.survophthal.2022.03.003_bib0034","doi-asserted-by":"crossref","first-page":"624","DOI":"10.1136\/bjo.77.10.624","article-title":"Clinical predictive factors for development of recurrence and metastasis in conjunctival melanoma: a review of 68 cases","volume":"77","author":"De Potter","year":"1993","journal-title":"Br J Ophthalmol"},{"issue":"8","key":"10.1016\/j.survophthal.2022.03.003_bib0035","doi-asserted-by":"crossref","first-page":"1058","DOI":"10.1016\/S0161-6420(88)33058-7","article-title":"Cryotherapy for conjunctival primary acquired melanosis and malignant melanoma. Experience with 62 cases","volume":"95","author":"Jakobiec","year":"1988","journal-title":"Ophthalmology"},{"issue":"4","key":"10.1016\/j.survophthal.2022.03.003_bib0036","doi-asserted-by":"crossref","first-page":"252","DOI":"10.1136\/bjo.78.4.252","article-title":"Prognostic factors in primary malignant melanoma of the conjunctiva: a clinicopathological study of 256 cases","volume":"78","author":"Paridaens","year":"1994","journal-title":"Br J Ophthalmol"},{"issue":"11","key":"10.1016\/j.survophthal.2022.03.003_bib0037","doi-asserted-by":"crossref","first-page":"1108","DOI":"10.1007\/s00417-004-1080-y","article-title":"Topical mitomycin chemotherapy for conjunctival malignant melanoma and primary acquired melanosis with atypia: 12 years' experience","volume":"243","author":"Kurli","year":"2005","journal-title":"Graefes Arch Clin Exp Ophthalmol"},{"issue":"7","key":"10.1016\/j.survophthal.2022.03.003_bib0038","doi-asserted-by":"crossref","first-page":"708","DOI":"10.1111\/j.1442-9071.2006.01356.x","article-title":"Role of topical chemotherapy for primary acquired melanosis and malignant melanoma of the conjunctiva and cornea: review of the evidence and recommendations for treatment","volume":"34","author":"Chalasani","year":"2006","journal-title":"Clin Exp Ophthalmol"},{"issue":"2","key":"10.1016\/j.survophthal.2022.03.003_bib0039","doi-asserted-by":"crossref","first-page":"229","DOI":"10.1016\/j.ajo.2004.08.065","article-title":"The treatment of primary acquired melanosis (PAM) with atypia by topical Mitomycin C","volume":"139","author":"Pe'er","year":"2005","journal-title":"Am J Ophthalmol"},{"issue":"2","key":"10.1016\/j.survophthal.2022.03.003_bib0040","doi-asserted-by":"crossref","first-page":"114","DOI":"10.1097\/00003226-200303000-00006","article-title":"Topical mitomycin C in the treatment of pigmented conjunctival lesions","volume":"22","author":"Rodr\u00edguez-Ares","year":"2003","journal-title":"Cornea"},{"key":"10.1016\/j.survophthal.2022.03.003_bib0041","doi-asserted-by":"crossref","DOI":"10.1155\/2013\/349162","article-title":"The use of strontium-90 Beta radiotherapy as adjuvant treatment for conjunctival melanoma","volume":"2013","author":"Cohen","year":"2013","journal-title":"J Oncol"},{"issue":"4","key":"10.1016\/j.survophthal.2022.03.003_bib0042","doi-asserted-by":"crossref","first-page":"293","DOI":"10.1111\/j.1442-9071.2010.02469.x","article-title":"Conservative resection and adjuvant plaque brachytherapy for early-stage conjunctival melanoma","volume":"39","author":"Karim","year":"2011","journal-title":"Clin Exp Ophthalmol"},{"issue":"7","key":"10.1016\/j.survophthal.2022.03.003_bib0043","doi-asserted-by":"crossref","first-page":"649","DOI":"10.1055\/s-2008-1027432","article-title":"Rezidivh\u00e4ufigkeit nach Exzision von Bindehautmelanomen und adjuvanter Strontium-90-Kontaktbestrahlung [Recurrence rate following adjuvant strontium-90 brachytherapy after excision of conjunctival melanoma]","volume":"225","author":"Krause","year":"2008","journal-title":"Klin Monbl Augenheilkd"},{"issue":"2","key":"10.1016\/j.survophthal.2022.03.003_bib0044","doi-asserted-by":"crossref","first-page":"119","DOI":"10.1038\/eye.2012.241","article-title":"Radiotherapy for ocular tumours","volume":"27","author":"Stannard","year":"2013","journal-title":"Eye (Lond)"},{"issue":"3","key":"10.1016\/j.survophthal.2022.03.003_bib0045","doi-asserted-by":"crossref","first-page":"133","DOI":"10.1159\/000310419","article-title":"Combined local excision and brachytherapy with ruthenium-106 in the treatment of epibulbar malignancies","volume":"207","author":"Zehetmayer","year":"1993","journal-title":"Ophthalmologica"},{"issue":"3","key":"10.1016\/j.survophthal.2022.03.003_bib0046","doi-asserted-by":"crossref","first-page":"503","DOI":"10.2147\/OPTH.S1606","article-title":"Topical treatment options for conjunctival neoplasms","volume":"2","author":"Kim","year":"2008","journal-title":"Clin Ophthalmol"},{"issue":"11","key":"10.1016\/j.survophthal.2022.03.003_bib0047","doi-asserted-by":"crossref","first-page":"751","DOI":"10.1136\/bjo.77.11.751","article-title":"Topical chemotherapy for conjunctival melanoma","volume":"77","author":"Finger","year":"1993","journal-title":"Br J Ophthalmol"},{"issue":"9","key":"10.1016\/j.survophthal.2022.03.003_bib0048","doi-asserted-by":"crossref","first-page":"1754","DOI":"10.1016\/j.ophtha.2011.01.060","article-title":"Outcomes in 15 patients with conjunctival melanoma treated with adjuvant topical mitomycin C: complications and recurrences","volume":"118","author":"Ditta","year":"2011","journal-title":"Ophthalmology"},{"issue":"1","key":"10.1016\/j.survophthal.2022.03.003_bib0049","doi-asserted-by":"crossref","first-page":"97","DOI":"10.1016\/j.survophthal.2013.01.003","article-title":"Local chemotherapeutic agents for the treatment of ocular malignancies","volume":"59","author":"Fernandes","year":"2014","journal-title":"Surv Ophthalmol"},{"issue":"7","key":"10.1016\/j.survophthal.2022.03.003_bib0050","first-page":"885","article-title":"Topical mitomycin chemotherapy for conjunctival malignant melanoma and primary acquired melanosis with atypia: clinical experience with histopathologic observations","volume":"118","author":"Demirci","year":"2000","journal-title":"Arch Ophthalmol"},{"issue":"10","key":"10.1016\/j.survophthal.2022.03.003_bib0051","doi-asserted-by":"crossref","first-page":"1316","DOI":"10.1136\/bjo.2009.176099","article-title":"Topical mitomycin C chemotherapy in the management of ocular surface neoplasia: a 10-year review of treatment outcomes and complications","volume":"94","author":"Russell","year":"2010","journal-title":"Br J Ophthalmol"},{"issue":"3","key":"10.1016\/j.survophthal.2022.03.003_bib0052","doi-asserted-by":"crossref","first-page":"185","DOI":"10.1586\/17469899.2014.921119","article-title":"Management of conjunctival malignant melanoma: a review and update","volume":"9","author":"Wong","year":"2014","journal-title":"Expert Rev Ophthalmol"},{"issue":"4","key":"10.1016\/j.survophthal.2022.03.003_bib0053","doi-asserted-by":"crossref","first-page":"746","DOI":"10.1016\/S0002-9394(03)00393-3","article-title":"Punctal-canalicular stenosis associated with mitomycin-C for corneal epithelial dysplasia","volume":"136","author":"Billing","year":"2003","journal-title":"Am J Ophthalmol"},{"issue":"1","key":"10.1016\/j.survophthal.2022.03.003_bib0054","doi-asserted-by":"crossref","first-page":"17","DOI":"10.1016\/j.ajo.2011.05.034","article-title":"Keratocyte density 3 months, 15 months, and 3 years after corneal surface ablation with mitomycin C","volume":"153","author":"de Benito-Llopis","year":"2012","journal-title":"Am J Ophthalmol"},{"issue":"6","key":"10.1016\/j.survophthal.2022.03.003_bib0055","doi-asserted-by":"crossref","first-page":"562","DOI":"10.3928\/1081-597X-20060601-08","article-title":"Effect of prophylactic and therapeutic mitomycin C on corneal apoptosis, cellular proliferation, haze, and long-term keratocyte density in rabbits","volume":"22","author":"Netto","year":"2006","journal-title":"J Refract Surg"},{"issue":"2","key":"10.1016\/j.survophthal.2022.03.003_bib0056","doi-asserted-by":"crossref","first-page":"375","DOI":"10.1016\/S0002-9394(03)00207-1","article-title":"Intumescent cataract after topical mitomycin-C for conjunctival malignant melanoma","volume":"136","author":"Sacu","year":"2003","journal-title":"Am J Ophthalmol"},{"issue":"3","key":"10.1016\/j.survophthal.2022.03.003_bib0057","doi-asserted-by":"crossref","first-page":"461","DOI":"10.1016\/j.survophthal.2020.09.004","article-title":"Clinical treatment options for early-stage and advanced conjunctival melanoma","volume":"66","author":"Zeng","year":"2021","journal-title":"Surv Ophthalmol"},{"issue":"2","key":"10.1016\/j.survophthal.2022.03.003_bib0058","doi-asserted-by":"crossref","first-page":"133","DOI":"10.1159\/000452473","article-title":"Systemic BRAF\/MEK inhibitors as a potential treatment option in metastatic conjunctival melanoma","volume":"3","author":"Mor","year":"2017","journal-title":"Ocul Oncol Pathol"},{"key":"10.1016\/j.survophthal.2022.03.003_bib0059","article-title":"Systemic treatment of metastatic conjunctival melanoma","volume":"2017","author":"Pinto Torres","year":"2017","journal-title":"Case Rep Oncol Med"},{"key":"10.1016\/j.survophthal.2022.03.003_bib0060","doi-asserted-by":"crossref","first-page":"232","DOI":"10.3389\/fonc.2019.00232","article-title":"Dabrafenib and trametinib in BRAF mutant metastatic conjunctival melanoma","volume":"9","author":"Rossi","year":"2019","journal-title":"Front Oncol"},{"issue":"1","key":"10.1016\/j.survophthal.2022.03.003_bib0061","doi-asserted-by":"crossref","first-page":"83","DOI":"10.1186\/s40425-019-0555-7","article-title":"Checkpoint inhibition immunotherapy for advanced local and systemic conjunctival melanoma: a clinical case series","volume":"7","author":"Finger","year":"2019","journal-title":"J Immunother Cancer"},{"issue":"11","key":"10.1016\/j.survophthal.2022.03.003_bib0062","doi-asserted-by":"crossref","first-page":"1236","DOI":"10.1001\/jamaophthalmol.2018.3488","article-title":"Immunotherapy with programmed cell death 1 inhibitors for 5 patients with conjunctival melanoma","volume":"136","author":"Sagiv","year":"2018","journal-title":"JAMA Ophthalmol"},{"issue":"5","key":"10.1016\/j.survophthal.2022.03.003_bib0063","doi-asserted-by":"crossref","first-page":"259","DOI":"10.1089\/jir.2018.0125","article-title":"Interferon alpha 2a and 2b in ophthalmology: a review","volume":"39","author":"Lewczuk","year":"2019","journal-title":"J Interferon Cytokine Res"},{"issue":"4","key":"10.1016\/j.survophthal.2022.03.003_bib0064","doi-asserted-by":"crossref","first-page":"506","DOI":"10.1097\/ICO.0000000000001153","article-title":"Immunosuppression as a possible risk factor for interferon nonresponse in ocular surface squamous neoplasia","volume":"36","author":"Ashkenazy","year":"2017","journal-title":"Cornea"},{"issue":"4","key":"10.1016\/j.survophthal.2022.03.003_bib0065","doi-asserted-by":"crossref","first-page":"568","DOI":"10.1016\/j.ajo.2006.05.058","article-title":"Topical interferon alfa-2b for the treatment of recalcitrant ocular surface squamous neoplasia","volume":"142","author":"Holcombe","year":"2006","journal-title":"Am J Ophthalmol"},{"issue":"3","key":"10.1016\/j.survophthal.2022.03.003_bib0066","doi-asserted-by":"crossref","first-page":"317","DOI":"10.1016\/S0181-5512(08)74813-7","article-title":"Treatment of conjunctival squamous neoplasias with interferon alpha 2ab","volume":"31","author":"Huerva","year":"2008","journal-title":"J Fr Ophtalmol"},{"issue":"10","key":"10.1016\/j.survophthal.2022.03.003_bib0067","doi-asserted-by":"crossref","first-page":"1220","DOI":"10.1097\/01.ico.0000240088.38631.46","article-title":"Short-term mitomycin C followed by long-term interferon alpha 2 beta for conjunctiva-cornea intraepithelial neoplasia","volume":"25","author":"Huerva","year":"2006","journal-title":"Cornea"},{"issue":"6","key":"10.1016\/j.survophthal.2022.03.003_bib0068","doi-asserted-by":"crossref","first-page":"1093","DOI":"10.1016\/S0161-6420(01)00577-2","article-title":"Treatment of conjunctival and corneal intraepithelial neoplasia with topical interferon alpha-2b","volume":"108","author":"Karp","year":"2001","journal-title":"Ophthalmology"},{"issue":"2","key":"10.1016\/j.survophthal.2022.03.003_bib0069","doi-asserted-by":"crossref","first-page":"268","DOI":"10.1016\/S0002-9394(02)01514-3","article-title":"Treatment of conjunctival papillomata with topical interferon Alfa-2b","volume":"134","author":"Schechter","year":"2002","journal-title":"Am J Ophthalmol"},{"issue":"10","key":"10.1016\/j.survophthal.2022.03.003_bib0070","doi-asserted-by":"crossref","first-page":"1375","DOI":"10.1001\/jama.1991.03470100067035","article-title":"The interferons. Mechanisms of action and clinical applications","volume":"266","author":"Baron","year":"1991","journal-title":"JAMA"},{"issue":"2","key":"10.1016\/j.survophthal.2022.03.003_bib0071","doi-asserted-by":"crossref","first-page":"119","DOI":"10.1016\/S1359-6101(01)00022-3","article-title":"Interferon-alpha in tumor immunity and immunotherapy","volume":"13","author":"Belardelli","year":"2002","journal-title":"Cytokine Growth Factor Rev"},{"issue":"6-7","key":"10.1016\/j.survophthal.2022.03.003_bib0072","doi-asserted-by":"crossref","first-page":"884","DOI":"10.1016\/j.biochi.2007.04.006","article-title":"Interferon-alpha and cancer: mechanisms of action and new perspectives of clinical use","volume":"89","author":"Ferrantini","year":"2007","journal-title":"Biochimie"},{"issue":"3","key":"10.1016\/j.survophthal.2022.03.003_bib0073","doi-asserted-by":"crossref","first-page":"219","DOI":"10.1038\/s41573-018-0011-2","article-title":"Interferons \u03b1 and \u03b2 in cancer: therapeutic opportunities from new insights","volume":"18","author":"Borden","year":"2019","journal-title":"Nat Rev Drug Discov"},{"issue":"4","key":"10.1016\/j.survophthal.2022.03.003_bib0074","first-page":"397","article-title":"Brysk MM. Discrimination between nonmalignant and malignant cells by combinations of IFN-gamma and IFN-alpha\/beta","volume":"3","author":"Fleischmann","year":"1984","journal-title":"J Biol Response Mod"},{"issue":"2","key":"10.1016\/j.survophthal.2022.03.003_bib0075","doi-asserted-by":"crossref","first-page":"284","DOI":"10.1016\/j.ejca.2009.10.013","article-title":"Redefining the role of interferon in the treatment of malignant diseases","volume":"46","author":"Bracarda","year":"2010","journal-title":"Eur J Cancer"},{"issue":"12","key":"10.1016\/j.survophthal.2022.03.003_bib0076","doi-asserted-by":"crossref","first-page":"2241","DOI":"10.1016\/j.ophtha.2010.03.052","article-title":"Subconjunctival\/perilesional recombinant interferon \u03b12b for ocular surface squamous neoplasia: a 10-year review","volume":"117","author":"Karp","year":"2010","journal-title":"Ophthalmology"},{"issue":"1","key":"10.1016\/j.survophthal.2022.03.003_bib0077","doi-asserted-by":"crossref","first-page":"91","DOI":"10.1016\/S0161-6420(99)90009-X","article-title":"Perilesional and topical interferon alfa-2b for conjunctival and corneal neoplasia","volume":"106","author":"Vann","year":"1999","journal-title":"Ophthalmology"},{"issue":"7","key":"10.1016\/j.survophthal.2022.03.003_bib0078","doi-asserted-by":"crossref","first-page":"726","DOI":"10.1097\/01.ico.0000126320.36014.d1","article-title":"Adjunctive treatment with interferon alpha-2b may decrease the risk of papilloma-associated conjunctival intraepithelial neoplasm recurrence","volume":"23","author":"Chen","year":"2004","journal-title":"Cornea"},{"issue":"1","key":"10.1016\/j.survophthal.2022.03.003_bib0079","doi-asserted-by":"crossref","first-page":"111","DOI":"10.1007\/s00417-009-1189-0","article-title":"Interferon alpha for the treatment of melanocytic conjunctival lesions","volume":"248","author":"Herold","year":"2010","journal-title":"Graefes Arch Clin Exp Ophthalmol"},{"issue":"11","key":"10.1016\/j.survophthal.2022.03.003_bib0080","doi-asserted-by":"crossref","first-page":"558","DOI":"10.1016\/j.oftal.2018.06.008","article-title":"Resolution of conjunctival melanoma with topical interferon alpha 2b in a patient with mitomycin C intolerance","volume":"93","author":"Chaparro Tapias","year":"2018","journal-title":"Arch Soc Esp Oftalmol"},{"issue":"2","key":"10.1016\/j.survophthal.2022.03.003_bib0081","doi-asserted-by":"crossref","first-page":"284","DOI":"10.3109\/09273948.2015.1115880","article-title":"Topical Interferon Alpha-2b for Diffuse Conjunctival Primary Acquired Melanosis with Atypia","volume":"25","author":"Huerva","year":"2017","journal-title":"Ocul Immunol Inflamm"},{"issue":"11","key":"10.1016\/j.survophthal.2022.03.003_bib0082","first-page":"1043","volume":"115","author":"Kase","year":"2011","journal-title":"Nippon Ganka Gakkai Zasshi"},{"issue":"1","key":"10.1016\/j.survophthal.2022.03.003_bib0083","doi-asserted-by":"crossref","first-page":"84","DOI":"10.4103\/2008-322X.156127","article-title":"Resolution of primary acquired melanosis with atypia after treatment with topical mitomycin C and interferon alfa-2b","volume":"10","author":"Ghassemi","year":"2015","journal-title":"J Ophthalmic Vis Res"},{"issue":"9","key":"10.1016\/j.survophthal.2022.03.003_bib0084","doi-asserted-by":"crossref","first-page":"1755","DOI":"10.1016\/j.ophtha.2004.01.034","article-title":"Treatment of recurrent corneal and conjunctival intraepithelial neoplasia with topical interferon alfa 2b","volume":"111","author":"Boehm","year":"2004","journal-title":"Ophthalmology"},{"issue":"6","key":"10.1016\/j.survophthal.2022.03.003_bib0085","doi-asserted-by":"crossref","first-page":"782","DOI":"10.1016\/S0002-9394(01)00836-4","article-title":"Retinopathy associated with high-dose interferon alfa-2b therapy","volume":"131","author":"Hejny","year":"2001","journal-title":"Am J Ophthalmol"},{"issue":"1","key":"10.1016\/j.survophthal.2022.03.003_bib0086","doi-asserted-by":"crossref","first-page":"58","DOI":"10.1097\/00003226-198903000-00010","article-title":"Lack of toxicity of a topical recombinant interferon alpha","volume":"8","author":"Smith","year":"1989","journal-title":"Cornea"},{"issue":"8","key":"10.1016\/j.survophthal.2022.03.003_bib0087","doi-asserted-by":"crossref","first-page":"1291","DOI":"10.1016\/j.ophtha.2007.10.039","article-title":"Long-term follow-up of conjunctival and corneal intraepithelial neoplasia treated with topical interferon alfa-2b","volume":"115","author":"Schechter","year":"2008","journal-title":"Ophthalmology"},{"issue":"1","key":"10.1016\/j.survophthal.2022.03.003_bib0088","doi-asserted-by":"crossref","first-page":"6","DOI":"10.1097\/00003226-200201000-00003","article-title":"Regression of Presumed Primary Conjunctival and Corneal Intraepithelial Neoplasia With Topical Interferon Alpha-2b","volume":"21","author":"Schechter","year":"2002","journal-title":"Cornea"},{"issue":"8","key":"10.1016\/j.survophthal.2022.03.003_bib0089","doi-asserted-by":"crossref","first-page":"1087","DOI":"10.1136\/bjo.2006.107482","article-title":"Ocular surface toxicity associated with topical interferon alpha-2b","volume":"91","author":"Aldave","year":"2007","journal-title":"Br J Ophthalmol"},{"issue":"9","key":"10.1016\/j.survophthal.2022.03.003_bib0090","doi-asserted-by":"crossref","first-page":"873","DOI":"10.1093\/ptj\/89.9.873","article-title":"Reprint\u2013preferred reporting items for systematic reviews and meta-analyses: the PRISMA statement","volume":"89","author":"Moher","year":"2009","journal-title":"Phys Ther"},{"key":"10.1016\/j.survophthal.2022.03.003_bib0091","author":"L\u00f3pez de Argumedo","year":"2017"},{"issue":"1","key":"10.1016\/j.survophthal.2022.03.003_bib0092","doi-asserted-by":"crossref","first-page":"90","DOI":"10.1097\/ICO.0000000000000277","article-title":"Combination topical therapy for conjunctival primary acquired melanosis with atypia and periocular lentigo maligna","volume":"34","author":"Bratton","year":"2015","journal-title":"Cornea"},{"issue":"8","key":"10.1016\/j.survophthal.2022.03.003_bib0093","doi-asserted-by":"crossref","first-page":"3167","DOI":"10.1073\/pnas.90.8.3167","article-title":"Differentiation-dependent activation of interferon-stimulated gene factors and transcription factor NF-kappa B in mouse embryonal carcinoma cells","volume":"90","author":"Kalvakolanu","year":"1993","journal-title":"Proc Natl Acad Sci U S A."},{"issue":"25","key":"10.1016\/j.survophthal.2022.03.003_bib0094","first-page":"9742","article-title":"Modulation of interferon action by retinoids. Induction of murine STAT1 gene expression by retinoic acid [published correction appears in","volume":"272","author":"Kolla","year":"1997","journal-title":"J Biol Chem"},{"issue":"10","key":"10.1016\/j.survophthal.2022.03.003_bib0095","doi-asserted-by":"crossref","first-page":"1368","DOI":"10.1001\/archophthalmol.2010.241","article-title":"Rapid response of refractory ocular surface dysplasia to combination treatment with topical all-trans retinoic acid and interferon alfa-2b","volume":"128","author":"Skippen","year":"2010","journal-title":"Arch Ophthalmol"},{"issue":"10","key":"10.1016\/j.survophthal.2022.03.003_bib0096","doi-asserted-by":"crossref","first-page":"1969","DOI":"10.1016\/j.ophtha.2012.03.045","article-title":"Treatment of conjunctival and corneal epithelial neoplasia with retinoic acid and topical interferon alfa-2b: long-term follow-up","volume":"119","author":"Krilis","year":"2012","journal-title":"Ophthalmology"},{"issue":"8","key":"10.1016\/j.survophthal.2022.03.003_bib0097","doi-asserted-by":"crossref","first-page":"e55","DOI":"10.1016\/j.ophtha.2013.05.023","article-title":"Treatment of CIN with retinoic acid and topical interferon alfa-2b","volume":"120","author":"Huerva","year":"2013","journal-title":"Ophthalmology"},{"issue":"3","key":"10.1016\/j.survophthal.2022.03.003_bib0098","doi-asserted-by":"crossref","first-page":"354","DOI":"10.1016\/j.jtos.2020.04.004","article-title":"The treatment of recurrent conjunctival and corneal intraepithelial neoplasia with interferon alfa-2b and retinoic acid: \u223c9 years' follow-up on tumor control","volume":"18","author":"Ip","year":"2020","journal-title":"Ocul Surf"},{"issue":"7","key":"10.1016\/j.survophthal.2022.03.003_bib0099","doi-asserted-by":"crossref","first-page":"944","DOI":"10.1136\/bjophthalmol-2015-307411","article-title":"Treatment of partial limbal stem cell deficiency with topical interferon \u03b1-2b and retinoic acid","volume":"100","author":"Tan","year":"2016","journal-title":"Br J Ophthalmol"},{"issue":"1","key":"10.1016\/j.survophthal.2022.03.003_bib0100","doi-asserted-by":"crossref","first-page":"14","DOI":"10.1016\/j.canlet.2006.11.019","article-title":"Tumor-suppressive activity of retinoic acid receptor-beta in cancer","volume":"253","author":"Xu","year":"2007","journal-title":"Cancer Lett"},{"issue":"2","key":"10.1016\/j.survophthal.2022.03.003_bib0101","doi-asserted-by":"crossref","first-page":"103","DOI":"10.1080\/15592294.2014.1003746","article-title":"Epigenetic regulation in human melanoma: past and future","volume":"10","author":"Sarkar","year":"2015","journal-title":"Epigenetics"},{"issue":"12","key":"10.1016\/j.survophthal.2022.03.003_bib0102","doi-asserted-by":"crossref","first-page":"1994","DOI":"10.1016\/j.ophtha.2018.07.002","article-title":"Primary acquired melanosis treated with combination interferon and retinoic acid","volume":"125","author":"Ip","year":"2018","journal-title":"Ophthalmology"},{"issue":"9","key":"10.1016\/j.survophthal.2022.03.003_bib0103","doi-asserted-by":"crossref","first-page":"e67","DOI":"10.1016\/j.ophtha.2019.03.026","article-title":"Primary acquired melanosis treated with combination interferon and retinoic acid (Ophthalmology 2018;125:1994-1996)","volume":"126","author":"Ip","year":"2019","journal-title":"Ophthalmology"},{"issue":"2","key":"10.1016\/j.survophthal.2022.03.003_bib0104","doi-asserted-by":"crossref","first-page":"204","DOI":"10.5301\/ejo.5001035","article-title":"Mitomycin C or interferon as adjuvant therapy to surgery for ocular surface squamous neoplasia: comparative study","volume":"28","author":"Blasi","year":"2018","journal-title":"Eur J Ophthalmol"},{"issue":"2","key":"10.1016\/j.survophthal.2022.03.003_bib0105","doi-asserted-by":"crossref","first-page":"460","DOI":"10.1038\/eye.2017.196","article-title":"Immunoreduction of ocular surface tumours with intralesional interferon alpha-2a","volume":"32","author":"Kim","year":"2018","journal-title":"Eye (Lond)"},{"issue":"4","key":"10.1016\/j.survophthal.2022.03.003_bib0106","doi-asserted-by":"crossref","first-page":"539","DOI":"10.1053\/j.seminoncol.2015.05.015","article-title":"Anticancer Cytokines: Biology and Clinical Effects of Interferon-\u03b12, Interleukin (IL)-2, IL-15, IL-21, and IL-12","volume":"42","author":"Floros","year":"2015","journal-title":"Semin Oncol"}],"container-title":["Survey of Ophthalmology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S003962572200039X?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S003962572200039X?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2025,9,22]],"date-time":"2025-09-22T11:54:38Z","timestamp":1758542078000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S003962572200039X"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2022,9]]},"references-count":106,"journal-issue":{"issue":"5","published-print":{"date-parts":[[2022,9]]}},"alternative-id":["S003962572200039X"],"URL":"https:\/\/doi.org\/10.1016\/j.survophthal.2022.03.003","relation":{},"ISSN":["0039-6257"],"issn-type":[{"value":"0039-6257","type":"print"}],"subject":[],"published":{"date-parts":[[2022,9]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Use of interferon alpha 2b to manage conjunctival primary acquired melanosis and conjunctival melanoma","name":"articletitle","label":"Article Title"},{"value":"Survey of Ophthalmology","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.survophthal.2022.03.003","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2022 Elsevier Inc. All rights reserved.","name":"copyright","label":"Copyright"}]}}